Core Viewpoint - Jindalai (688057.SH) plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, aiming to optimize its industrial structure and seek new growth opportunities [1] Group 1: Investment Details - The investment will be made using the company's own funds amounting to 30 million yuan [1] - After the investment, Jindalai will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Company Background - Zhongke Hongtai specializes in the research, production, and sales of medical robot technology and systems [1] - The company was incubated by the Institute of Automation, Chinese Academy of Sciences, and is led by a team of experts including Professor Hou Zengguang [1] - Since 2008, the founding team has undertaken over 10 major projects, including the first domestic 863 program for vascular interventional surgical robots [1] Group 3: Financial Status and Purpose of Investment - Zhongke Hongtai is currently not profitable [1] - The investment aims to enhance the company's risk resistance and cultivate new profit growth points [1] - Funds from the investment will be allocated for technology research and development, market promotion, and daily operations [1]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to seek new opportunities for growth and enhance its risk resistance [1] Group 1: Investment and Financial Actions - The company plans to invest RMB 30 million in Zhongke Hongtai, with RMB 1.9586895 million allocated for subscribing to the new registered capital of Zhongke Hongtai and the remaining RMB 28.0413105 million to be added to the capital reserve [1] - After the completion of this transaction, the company will hold a 10.00% equity stake in Zhongke Hongtai [1]

证券代码：688057 证券简称：金达莱 公告编号：2025-035 江西金达莱环保股份有限公司 关于自愿披露对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：北京中科鸿泰医疗科技有限公司（以下简称"中科鸿泰"、 "标的公司"） 投资金额：江西金达莱环保股份有限公司（以下简称"公司"、"金达 莱"）拟使用自有资金 3000 万元向中科鸿泰增资，交易完成后公司将持有中 科鸿泰 10.00%的股权 已履行的审议程序：本次对外投资事项已经公司内部审议程序批准， 无需提交董事会、股东会审议通过。本次对外投资不构成《上市公司重大资 产重组管理办法》规定的重大资产重组，亦不构成关联交易。 相关风险提示：标的公司目前尚未盈利，实际经营过程中可能受行业 政策、市场准入、市场推广、运营管理等因素的影响，未来具体经营业绩及 投资收益仍存在不确定性。敬请广大投资者谨慎决策，注意投资风险。 一、对外投资概述 （一）本次交易概况 1、本次交易概况 1 / 7 公司基于对医疗机器人技术与系统的研发及应用等国家战 ...

Core Viewpoint - The company Jindalai (688057) plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake in the company [1] Group 1: Company Overview - Zhongke Hongtai specializes in the research, development, production, and sales of medical robot technology and systems [1] - The company was incubated by the Institute of Automation, Chinese Academy of Sciences, and is led by a team of experts including Professor Hou Zengguang, who has been involved in significant projects since 2008 [1] - Zhongke Hongtai is recognized as a pioneer in the field of vascular interventional surgical robots in China, having undertaken over 10 major projects, including the first domestic 863 program for vascular interventional surgical robots [1] Group 2: Financial Status - Zhongke Hongtai is currently not profitable [1]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a strategic investment in Zhongke Hongtai Medical Technology Co., Ltd. [1] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to capital reserves [1] - Upon completion of the transaction, the company will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular intervention surgical robot features significant advantages, including a bionic design that allows simultaneous rotation and pushing of guidewires [1] - The dual-channel design enables the operation of two guidewires and two balloon/stent catheters simultaneously, along with force feedback functionality [1] - The surgical robot can perform remote surgeries, provide full-process robotic assistance, and collect data, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, and improve overall competitiveness and influence, promoting sustainable development [2]

金达莱12月21日公告，公司拟使用自有资金3000万元向北京中科鸿泰医疗科技有限公司增资，其中 195.86895万元用于认购中科鸿泰195.86895万元的新增注册资本，剩余2804.13105万元计入资本公积。 本次交易完成后，公司将持有中科鸿泰10.00%的股权。 本次对外投资事项已经公司内部审议程序批准，无需提交董事会、股东会审议通过，亦不需要有关部门 批准。本次对外投资不构成《上市公司重大资产重组管理办法》规定的重大资产重组，亦不构成关联交 易。 ...

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Beijing Zhongke Hongtai Medical Technology Co., Ltd. [1][2] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to the capital reserve [1] - After the transaction, the company will hold a 10% stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular interventional surgical robot features significant advantages, including bionic design for simultaneous wire rotation and pushing operations, dual-channel design for operating two wires and two balloon/stent catheters simultaneously, and force feedback functionality [1] - The surgical robot can perform remote surgeries, full-process robotic assistance, and data collection, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research and development capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, improve overall competitiveness and influence, and promote sustainable development [2]

Core Viewpoint - The company intends to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, which has been approved internally and does not constitute a major asset restructuring or related party transaction [1] Group 1: Investment Details - The investment amount is 30 million yuan [1] - After the investment, the company will hold a 10% equity stake in Zhongke Hongtai [1] - The investment has received internal approval from the company [1] Group 2: Company Background - Zhongke Hongtai was founded by Professor Hou Zengguang's team and has strong research capabilities in the field of medical artificial intelligence [1] - The company's products have entered the special review process for innovative medical devices by the National Medical Products Administration [1] Group 3: Financial Performance - As of January to September 2025, Zhongke Hongtai reported revenue of 10.26 thousand yuan and a net loss of 550.77 thousand yuan [1] - The company is currently not profitable, indicating uncertainty in future operating performance and investment returns [1]

Group 1 - The core point of the article is that Jiangxi Jindalai Environmental Protection Co., Ltd. plans to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake, driven by optimism about the development prospects of stem cell technology and its applications [1][3] - Jindalai aims to optimize its industrial structure and seek new growth opportunities to enhance its risk resistance and cultivate new profit growth points through investments in strategic emerging industries like biomanufacturing and health care [3][4] Group 2 - Jindalai is recognized as an advanced innovative comprehensive service provider for water environment governance, with its main products and services including water pollution control equipment and overall solutions for water environment [2] - The company's FMBR wastewater treatment system is characterized by simplicity, originality, and modernization, offering significant advantages over traditional wastewater treatment methods, such as reduced sludge volume and lower comprehensive costs [2] - Jici Medical specializes in the research and application of autologous cell technology, holding unique advantages in the field of cell reprogramming and rejuvenation, with a series of patented technologies for developing various functional cells [4][6] Group 3 - Jici Medical has developed an autologous rFib injection that has been tested for safety and efficacy across over 30 clinical indications, with plans to enter the pre-IND stage for some products [5][6] - The company has established multiple research platforms in collaboration with various institutions to promote technology transfer and high-end talent cultivation [5][6] - As of September 30, 2025, Jici Medical reported total assets of 10.01 million yuan, with revenues and net profits of 11.23 million yuan and 1.15 million yuan respectively, indicating a modest performance due to limited funding and small operational scale [6]

Core Viewpoint - Jindalai (688057) plans to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake to enhance its business and competitiveness [1] Group 1: Investment Details - The investment amount is 280 million yuan [1] - After the investment, Jindalai will hold a 34% equity stake in Jici Medical [1] Group 2: Business Focus - Jici Medical and its subsidiaries focus on the research and application of autologous cell technology [1] - The company has developed autologous rFib injection solutions that have undergone safety and efficacy validation for over 30 clinical indications [1] Group 3: Strategic Objectives - The purpose of the investment is to expand Jindalai's business and enhance its profitability [1] - The investment aims to improve the company's overall competitiveness and influence [1] - It is intended to promote the sustainable development of the company [1]